NCT03084887 (STEDC) is a NA clinical trial of manuals and follow-up in Tissue Expansion, sponsored by Xijing Hospital.

Who is sponsoring NCT03084887?

NCT03084887 is sponsored by Xijing Hospital.

What drugs are being tested in NCT03084887?

Interventions in NCT03084887: manuals and follow-up.

What condition does NCT03084887 study?

NCT03084887 studies Tissue Expansion.

Is NCT03084887 still recruiting?

NCT03084887 is currently status unknown. Last updated 21 March 2017.

Last reviewed 2017-03-21 · How we verify

NCT03084887: STEDC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tissue Expansion Devices Complications

Status unknown NA Last updated 21 March 2017

What this trial tests

NA trial testing manuals and follow-up in Tissue Expansion in 208 participants. Status unknown.

Timeline

10 November 2016

Primary endpoint
28 February 2018

28 February 2018

Quick facts

Lead sponsor	Xijing Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	208
Start date	10 November 2016
Primary completion	28 February 2018
Estimated completion	28 February 2018
Sites	1 location across China

Drugs / interventions tested

manuals and follow-up

Conditions studied

Tissue Expansion — all drugs for Tissue Expansion →

Sponsor

Xijing Hospital

Who can join

Adults 1 to 70, any sex, with Tissue Expansion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reduce the common complications incidence about patients placed tissue expansion devices to around 5%.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03084887 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 21 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03084887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing